IMR Press / EJGO / Volume 25 / Issue 3 / pii/2004175

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Role of plasma nitric oxide in complete hydatidiform mole

Show Less
1 Departments of Gynecology and Obstetrics, University of Harran, Faculty of Medicine, Sanliurfa (Turkey)
2 Departments of Biochemistry, University of Harran, Faculty of Medicine, Sanliurfa (Turkey)
Eur. J. Gynaecol. Oncol. 2004, 25(3), 333–335;
Published: 10 June 2004

Purpose of investigation: This prospective study aimed to evaluate any relationship between development of complete hydatidi­form mole and plasma levels of nitric oxide (a biologically active mediator derived from L-arginine), and human chorionic gonadotropin β (β-hCG; a metabolite involved in trophoblast production). Methods: Levels of plasma nitric oxide and β-hCG were measured in 38 patients with complete hydatidiform mole pregnancies, and nitric oxide levels were measured in 31 women with normal pregnancies who formed the control group. Results: For patients compared with controls, mean plasma concentrations of nitric oxide were significantly higher (35.84 vs 29.54 µM; p < 0.001) and significantly associated with increased risk of hydatidiform mole ( odds ratio 1.0105, 95% confidence interval 1.0034-1.0176). No significant relationship was found between plasma levels of nitric oxide and β-hCG in the patient group. Conclusion: In patients with complete hydatidiform mole compared with controls, plasma nitric oxide levels were found to be significantly higher and associated with increased molar risk.

Hydatidiform mole
Nitric oxide
Back to top